晚期胃癌患者免疫治疗联合化疗对营养状况、外周血T淋巴细胞亚群变化及临床

Observation on the nutritional status, peripheral blood T lymphocyte subset changes and clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer <br>Abstract: <br>Objective: To <br>evaluate the clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer and the nutritional status, peripheral blood T lymphocyte subsets Group changes; <br><br>Methods: <br><br>60 patients with locally advanced gastric cancer were randomly divided into two groups: experimental group and control group, with 30 cases in each group. <br><br>The control group was given FOLFOX4 chemotherapy regimen, while the experimental group was combined with sintilimab injection on the basis of the control group's chemotherapy regimen. All patients were followed up for 6 to 12 months. Comparative analysis of the occurrence of adverse reactions after the end of each treatment cycle of the two groups of patients; clinical efficacy; improvement of nutritional and physical status; changes in the levels of T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+. <br><br>Results: The total effective rate of the experimental group was 70%, and the total effective rate of the control group was 43.3%. The experimental group was significantly better than the control group (p=0.04); the incidence of adverse reactions in the experimental group was 50%, and the incidence of adverse reactions in the control group was 36.7%. The incidence of adverse reactions between the two groups was not statistically significant (p=0.30). The improvement rate of ECOG in the experimental group after treatment was significantly higher than that in the control group (p=0.03). After treatment, hemoglobin, albumin, serum iron and ferritin levels in the experimental group improved more significantly than those in the control group, and the difference was statistically significant. Academic meaning (p

The combination chemotherapy of immunotherapy in patients with advanced stomach cancer was observed on nutritional status, changes in the sub-groups of outer blood T lymphocytes and clinical efficacy<br>Summary:<br>Objective:<br>The clinical efficacy of immuno-combined chemotherapy for patients with advanced stomach cancer and the changes in the nutritional status and subsysty of extrinsic blood T lymphocytes were evaluated.<br><br>Method:<br><br>Sixty patients with local advanced gastric cancer were randomly divided into two groups: the experimental group and the control group, each with 30 cases.<br><br>The control group was given FOLFOX4 chemotherapy, while the experimental group was given a combination of synthesizer static points on the basis of the control group chemotherapy program, and all patients were followed from June to December. The adverse reactions occurred at the end of each treatment cycle in two groups of patients, clinical efficacy, improvement of nutrition and physical condition, and changes in the level of T lymphocyte subgroups CD3, CD4, CD8, CD4 and/CD8.<br><br>Results: The total efficiency of the experimental group was 70%, and the total efficiency of the control group was 43.3%. The experimental group was significantly better than the control group (p-0.04), the rate of adverse reactions in the experimental group was 50%, the rate of adverse reactions in the control group was 36.7%, and the occurrence of adverse reactions between the two groups was not statistically significant (p-0.30). The improvement rate of physical condition score (ECOG) was significantly higher than that of the control group after treatment (p-0.03), and the hemoglobin, albumin, serum iron and ferrine water level of the experimental group after treatment was more obvious than that of the control group, and the difference was statistically significant (p).

Effect of immunotherapy combined with chemotherapy on nutritional status, peripheral blood T lymphocyte subsets and clinical efficacy in patients with advanced gastric cancer<br>Abstract:<br>Objective: To investigate the mechanism of the disease<br>Objective to evaluate the clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer and the changes of nutritional status and peripheral blood T lymphocyte subsets;<br>method:<br>60 patients with locally advanced gastric cancer were randomly divided into two groups: experimental group and control group, 30 cases in each group.<br>The control group was treated with FOLFOX4 chemotherapy, while the experimental group was treated with sindilimab injection on the basis of the control group chemotherapy. All patients were followed up for 6 to 12 months. The incidence of adverse reactions, clinical efficacy, improvement of nutritional and physical status, and changes of T lymphocyte subsets CD3 +, CD4 +, CD8 +, CD4 + / CD8 + were compared between the two groups at the end of each treatment cycle.<br>Results: the total effective rate was 70% in the experimental group and 43.3% in the control group. The experimental group was significantly better than the control group (P = 0.04); the incidence of adverse reactions was 50% in the experimental group and 36.7% in the control group, and the incidence of adverse reactions between the two groups was not statistically significant (P = 0.30). After treatment, the improvement rate of ECoG in the experimental group was significantly higher than that in the control group (P = 0.03). After treatment, the levels of hemoglobin, albumin, serum iron and ferritin in the experimental group were significantly better than those in the control group (P < 0.05)<br>